This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Charles Marwick

JAMA. 2000;283:1814-1815.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Washington—Despite recent studies reporting its efficacy in preventing flu, particularly in children, the latest live virus candidate vaccine against influenza (FluMist, Aviron, Mountain View, Calif), faces an uphill road on its way to licensure. Some evidence for this conclusion appears in a newly published report of a workshop held in December 1998 at the Paul Ehrlich Institute in Langen, Germany (Biologicals. In press).

The workshop was attended by representatives of US and European public health agencies, regulatory authorities, academic scientists, and manufacturers, said Reinhard Kurth, MD, president of the Paul Ehrlich Institute, in an interview.

Several live virus influenza vaccines have been developed in the past 25 years or so; the agent of current interest was devised in the late 1980s by Hunein F. Maassab, PhD, a professor in the University of Michigan School of Public Health. In this vaccine, three of the six nonstructural viral . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Influenza
Cifu and Levinson
JAMA 2000;284:2847-2849.
FULL TEXT